Fate Therapeutics is a biopharmaceutical company focused on developing innovative cellular therapies for cancer and autoimmune diseases
The company's research centers on harnessing the power of induced pluripotent stem cells to create off-the-shelf, personalized treatments that can be administered to patients with various medical conditions. By leveraging its proprietary technology and expertise in stem cell biology, Fate Therapeutics aims to improve patient outcomes through advanced and sustainable therapeutic options, with a particular emphasis on enhancing the immune system's ability to target and combat disease.
As the regular session of the US market on Wednesday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment.
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
Companies Reporting Before The Bell • Kosmos Energy (NYSEKOS) is projected to report quarterly earnings at $0.23 per share on revenue of $477.73 million.
U.S. stock futures were lower this morning, with the Dow Jones futures falling around 60 points on Wednesday. Shares of Pinstripes (NYSEPNST) shares fell in pre-market trading after surging 22% on Tuesday.
